GoodRx price target raised to $10 from $9 at Guggenheim

Guggenheim raised the firm’s price target on GoodRx to $10 from $9 and keeps a Buy rating on the shares following ” impressive results,” highlighted by FY24 EBITDA guidance that was about 10% above the Street view. The firm thinks the business momentum positions the company for high-single to low-double digit growth with EBITDA margin expansion, the analyst tells investors in a post-earnings note.